Andere Sprachen ExpreS2ion Biotech Holding AB

Aktien

A2APAB

SE0008348262

EXPRS2

Markt geschlossen - Nasdaq Stockholm Andere Börsenplätze 17:29:30 03.05.2024			% 5 Tage	% 1. Jan.
1.454 ^SEK	-45.34%		-46.93%	-31.09%

16.04.	ExpreS2ion gibt den Abschluss der GLP-Sicherheitsstudie für den Brustkrebs-Impfstoffkandidaten ES2B-C001 (HER2-VLP) bekannt	CI
21.02.	ExpreS2ion Biotech JV sichert sich 10 Millionen Euro nach Abschluss der COVID-19-Impfstoffstudie durch Bavarian Nordic	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Notice to attend the Annual General Meeting in ExpreS2ion Biotech Holding AB (publ)	10:30
ExpreS2ion announces a rights issue of units of approximately SEK 60 million	02.05.
ExpreS2ion to receive approximately SEK 22.5 million dividend payment from AdaptVac ApS	23.04.
ExpreS2ion changes dates for the annual general meeting and the publication of the annual report for 2023	16.04.
ExpreS2ion announces completion of GLP safety study for ES2B-C001 (HER2-VLP) breast cancer vaccine candidate	16.04.
ExpreS2ion Announces Completion of GLP Safety Study for ES2B-C001 (HER2-VLP) Breast Cancer Vaccine Candidate	16.04.
ExpreS2ion to present in investor and R&D events in March	15.04.
ExpreS2ion to present in investor and R&D events in March	29.02.
ExpreS2ion Biotech JV Secures EUR10 Million Following Bavarian Nordic's Completion of COVID-19 Vaccine Trial	21.02.
ExpreS2ion's Associated Company AdaptVac Receives Milestone Payment Following Completion of Bavarian Nordic's Clinical Phase III Study for the COVID-19 Vaccine	21.02.
ExpreS2ion announces financial results for the fourth quarter and full-year 2023	08.02.
ExpreS2ion to present in Redeye Fight Cancer event and the Bio Innovation Leaders Summit	22.01.
ExpreS2ion to present new Nipah virus vaccine project in upcoming webcast	12.12.
Pareto Securities publishes research report	04.12.
ExpreS2ion Biotech Unit Secures EUR8 Million Grant for Virus Vaccine Project; Shares Soar	01.12.
ExpreS2ion announces new EU-funded Horizon Europe grant award for Nipah virus vaccine development	01.12.
ExpreS2ion CEO interviewed, CFO provides update at life science investor conference, Analysguiden publishes research report	27.11.
ExpreS2ion announces financial results for the third quarter 2023	16.11.
ExpreS2ion Biotech Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	16.11.
ExpreS2ion Biotechnologies: Bulletin from the Extraordinary General Meeting of ExpreS2ion Biotech Holding AB held on 9 November 2023	09.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen ExpreS2ion Biotech Holding AB

Aktien

A2APAB

SE0008348262

EXPRS2

Andere Sprachen

Filter